We have spent years telling patients with PsA that weight loss may improve symptoms and reduce cardiometabolic risk. A new ACR 2026 abstract asks the more provocative question: could GLP-1–based therapy influence PsA outcomes even after accounting for the change on the scale?
Recent News
When axSpA does not respond to treatment and both the clinician and patient perceive this is a problem, we call it difficult to manage. Is the disease difficult, or are we failing to see it clearly?Read Article
As rheumatologists, we are trained to carefully analyze signs and symptoms, interpret laboratory parameters, understand radiologic findings, make complex clinical decisions, and utilize the growing array of immunomodulatory treatments available to treat an expanding spectrum of diseases. Over the past two decades, there has been an increasing emphasis on a treat-to-target approach, the target being remission.
It is encouraging to see a new treatment option for fibromyalgia after more than 15 years without a new FDA-approved therapy. But we should look beyond whether a trial met its statistical endpoint and ask a more practical question: how much better did patients actually feel?
ILD is a particularly worrisome systemic feature of SjD that may be associated with poorer quality of life outcomes and increased mortality. Prevalence of SjD-ILD has been quoted to occur in 10-20% of SjD patients; however, identification of SjD may vary widely based on the testing methodologies used.
Relapse after CD19 CAR-T was rare in lupus and common in anti-synthetase syndrome and Scl-70 scleroderma. Six of seven relapsing patients were treated with BCMA-directed therapy and responded again.

Poster Hall